Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

Inclusion Criteria Concurrent Medication: Allowed: Antiretroviral therapy, provided the patient has been on the same dose and drugs for 60 days prior to study entry. Patients must have: Documented HIV infection. CD4 lymphocyte count of > 300 cells/mm3. One plasma HIV-1 RNA level between >= 20,000 and < 120,000 copies/ml. Prior Medication: Allowed: Stable antiretroviral therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Presence of an AIDS defining opportunistic infection, including Kaposi's sarcoma. Allergy to influenza or pneumococcal vaccine or their components; to egg or egg products. Unexplained temperature >= 38.5 degrees C for 7 consecutive days within the 30 days prior to study entry. Concurrent participation in other experimental therapies. Concurrent Medication: Excluded: Systemic chemotherapy. Steroids. Corticosteroids. Vaccinations. Any new antiretroviral agents that the patient was not taking at the time of study entry and not prescribed by the study. Colony stimulating factors including G-CSF or rEPO. Immune modulators/immune based therapies. Concurrent Treatment: Excluded: Radiation therapy. Transfusion dependent patients. Patients with any of the following prior conditions are excluded: History of an AIDS defining opportunistic infection, including Kaposi's sarcoma (except limited cutaneous diseases [< 5 lesions]). History of acute or chronic pancreatitis. Prior Medication: Excluded: Prior treatment with 3TC. Excluded within 30 days of study entry: Treatment with immune modulators. Acute or chronic therapy for recognized infections (eg, influenza, HSV, VZV). Excluded within 1 year of study entry: Treatment with an influenza and/or pneumonia vaccine [AS PER AMENDMENT 1/23/97: influenza vaccine only]. [AS PER AMENDMENT 1/23/97: Excluded within 3 years of study entry: Pneumonia vaccine.]